STOCK TITAN
  1. Home
  2. News
  3. AMRN

Amarin Corporation plc - $AMRN STOCK NEWS

Welcome to our dedicated page for Amarin Corporation plc news (Ticker: $AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Corporation plc stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amarin Corporation plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amarin Corporation plc's position in the market.

News
 Amarin to Report Third Quarter 2023 Financial Results and Host Conference Call on November 1, 2023
Rhea-AI Summary
Amarin Corporation to host conference call to discuss Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
conferences earnings
-
News
Amarin to Present at the 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
Amarin CEO to participate in Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
-
News
Amarin Provides Pricing & Reimbursement Updates for VAZKEPA (icosapent ethyl) in The Netherlands and Italy
Rhea-AI Summary
Amarin Corporation announced pricing and reimbursement updates for VAZKEPA in the Netherlands and Italy. The Dutch Ministry of Health has approved VAZKEPA for national reimbursement to reduce the risk of cardiovascular events in statin-treated patients with established cardiovascular disease and elevated triglycerides. In Italy, AIFA has issued a decision to not reimburse VAZKEPA at this time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
News
Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel
Rhea-AI Summary
Amarin Corporation and Neopharm Israel have entered into an exclusive marketing and commercialization agreement for VAZKEPA in Israel. VAZKEPA is the first prescription treatment comprised solely of icosapent ethyl, a highly purified form of eicosapentaenoic acid. The agreement follows regulatory approval by Israel's Ministry of Health for VAZKEPA to reduce the risk of cardiovascular events in high-risk patients with elevated triglycerides. Heart disease is the second leading cause of death in Israel for individuals aged 45 and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
none
-
News
Scottish Medicines Consortium Accepts VAZKEPA® (icosapent ethyl) to Help Reduce Cardiovascular Risk for Patients in Scotland(1)
Rhea-AI Summary
Amarin Corporation plc (NASDAQ:AMRN) announces SMC acceptance of VAZKEPA® for reimbursement in Scotland for secondary prevention in high-risk statin-treated patients with established cardiovascular disease. The innovative treatment option aims to reduce the risk of subsequent cardiovascular events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
-
News
Amarin Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Amarin Corporation reported total net revenues of $80 million in the second quarter of 2023, with net product revenues of $65 million and $15 million in license and royalty revenues. The company achieved positive cash flow of $9 million and has a cash position of $313 million. They implemented a cost reduction plan expected to save $40 million over 12 months. The Spanish Drug Pricing Committee recommended national reimbursement of VAZKEPA® in Spain. U.S. product net revenue declined by 22% sequentially to $64.6 million. Amarin is actively filing regulatory submissions for approval in 20 additional countries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Rhea-AI Summary
Amarin Corporation and Lotus Pharmaceuticals have formed a partnership to distribute and commercialize VAZKEPA across 10 countries, including nine in Southeast Asia and South Korea. VAZKEPA is an innovative treatment option to reduce cardiovascular risk. The partnership will help Amarin expand patient access to VAZKEPA and fuel international growth. The ASEAN region and South Korea have a total hyperlipidemia market of approximately $2 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
partnership
-
News
Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
-
News
Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
News
Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt
Rhea-AI Summary
Amarin Corporation announces the compensation program for its new President and CEO, Patrick Holt. The majority of Holt's total target compensation is tied to the creation of shareholder value through stock options. He will be issued a one-time grant of stock options to purchase up to 5,000,000 shares, subject to performance-based vesting with share price hurdles ranging from $2.50 to $15.00. Holt has also agreed to purchase $300,000 worth of Amarin shares in the open market using personal funds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
management
Stock AMRN logo
Amarin Corporation plc

Nasdaq:AMRN

AMRN Rankings

#3319 Ranked by Market Cap
#4474 Ranked by Stock Gains
N/A Ranked by Dividends

AMRN Stock Data

348.21M
383.11M
1.54%
23.81%
4.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DUBLIN 2

About AMRN

amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.